These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 31431482)

  • 1. Correction: The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    CMAJ Open; 2019; 7(3):E510. PubMed ID: 31431482
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of the introduction of a formulary into a large Canadian private drug plan: an interrupted time-series analysis.
    Cassels A; Law MR
    CMAJ Open; 2019; 7(3):E472-E477. PubMed ID: 31320330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.
    Burden AM; Tadrous M; Calzavara A; Cadarette SM
    Osteoporos Int; 2015 May; 26(5):1525-33. PubMed ID: 25603794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a value-based formulary in three chronic disease cohorts.
    Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.
    Foroutan N; Tarride JE; Xie F; Mills F; Levine M
    Pharmacoecon Open; 2019 Dec; 3(4):437-451. PubMed ID: 31041614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of formulary restriction on the relative consumption of carbapenems in intensive care units at an academic medical center.
    Pierce JW; Kirk A; Lee KB; Markley JD; Pakyz A; Bearman G; Doll ME; Stevens MP
    Infect Control Hosp Epidemiol; 2019 Sep; 40(9):1056-1058. PubMed ID: 31232265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incentive formularies and changes in prescription drug spending.
    Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process.
    Shalansky SJ; Virk R; Ackman M; Jackevicius C; Kertland H; Tsuyuki R; Humphries K;
    Can J Cardiol; 2003 Feb; 19(2):173-9. PubMed ID: 12601443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of patient and plan design factors on switching to preferred statin therapy.
    Cox ER; Kulkarni A; Henderson R
    Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel formulary: collaboration between health care professionals, seniors, private sector and government in Nova Scotia.
    Carruthers SG
    CMAJ; 1999 Jul; 161(1):58-61. PubMed ID: 10420868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
    Bosso JA; Mauldin PD
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2106-12. PubMed ID: 16723572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.
    Jandoc R; Burden AM; Mamdani M; Lévesque LE; Cadarette SM
    J Clin Epidemiol; 2015 Aug; 68(8):950-6. PubMed ID: 25890805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Financial Impact of Advanced Kidney Disease on Canada Pension Plan and Private Disability Insurance Costs.
    Manns B; McKenzie SQ; Au F; Gignac PM; Geller LI;
    Can J Kidney Health Dis; 2017; 4():2054358117703986. PubMed ID: 28491340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTEGRATING HEALTH TECHNOLOGY ASSESSMENT PRINCIPLES IN FORMULARY MANAGEMENT.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP
    Int J Technol Assess Health Care; 2016 Jan; 32(1-2):81-7. PubMed ID: 27001376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of ticagrelor formulary tiers in the USA: targeting private insurance providers away from government-funded plans.
    Serebruany VL; Dinicolantonio JJ
    Cardiology; 2013; 126(3):187-90. PubMed ID: 24030166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.
    Cristofaro JV; Ansher SS; Zwiebel JA; Ivy P; Conley B; Abrams JS; Doroshow JH
    Clin Pharmacol Ther; 2017 May; 101(5):616-618. PubMed ID: 27981567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Implementation of the Canadian Cardiovascular Society guidelines for perioperative risk assessment and management: an interrupted time series study.
    McIsaac DI; Montroy J; Gagne S; Johnson C; Ernst J; Halman S; Oake J; Chan J; Madden S; Feng S; Moody M; Simard CG; Taljaard M; Foster M; Fergusson DA; Lalu MM
    Can J Anaesth; 2022 Jun; 69(6):803-804. PubMed ID: 35318611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.